Randomized Controlled Trial of Labetalol Versus Hydralazine for Severe Hypertension in Obstetric Patients.

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 190 participants.

Also called NCT02050529

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 190 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02050529
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Pakistan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02050529. Randomized; single masking; primary purpose treatment. Start 2012-10 (actual); primary completion 2014-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Randomized Controlled Trial of Labetalol Versus Hydralazine for Severe Hypertension in Obstetric Patients.
Condition
Hypertension, Pregnancy Induced
Condition
Hydralazine Adverse Reaction
Condition
Pre-eclampsia
Condition
Pre-eclampsia Superimposed Pre-existing Hypertension
Intervention (Drug)
Labetalol
Intervention (Drug)
Hydralazine
Lead sponsor
Dow University of Health Sciences (class: other)

Record details

Record id
cardio:ct-nct02050529
Content hash
68b3880c8b231caf59f295b04875aae940f0f2820b15a9271629eec81b769421